Sutro Biopharma Q2 revenue rises to $63.7 mln, net loss narrows

Sutro Biopharma

07/08/2025 21:48

Overview

Sutro Q2 revenue rises to $63.7 mln, driven by Astellas collaboration

Operating expenses decreased, contributing to a reduced net loss

Outlook

Sutro sees restructuring and related costs, mostly in 2025, for deprioritization of the luvelta program

Sutro has cash runway extending into early 2027

Result Drivers

ASTELLAS COLLABORATION - Revenue boost attributed to collaboration with Astellas and recognition of deferred revenue from Ipsen's decision not to advance STRO-003

COSTS - Restructuring and and related costs were $18.4 mln, operating costs drop

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$63.74 mln
Q2 Net Income
-$11.50 mln
Q2 Basic EPS
-$0.14
Q2 Operating Expenses
$67.09 mln
Q2 Operating Income
-$3.34 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Sutro Biopharma Inc is $2.00, about 59.1% above its August 6 closing price of $0.82

Press Release: ID:nGNX1YGnF6

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)